• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Illumina Inc.

    4/9/25 4:51:02 PM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email
    DEFA14A 1 d910798ddefa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Under Rule 14a-12

    Illumina, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


    LOGO

    ILLUMINA, INC. 5200 ILLUMINA WAY SAN DIEGO, CA 92122 ATIN: BRIAN BLANCHED
    Your Vote Counts!
    ILLUMINA, INC.
    2025 Annual Meeting
    Vote by May 20, 2025
    11 :59 PM ET
    You invested in ILLUMINA, INC. and it’s time to vote!
    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 21, 2025.
    Get informed before you vote
    View the Notice & Proxy Statement, Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 07, 202 5. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.
    Smartphone users Vote Virtually at the Meeting*
    Point your camera here and May21,2025
    10:00 AM PDT
    vote without entering a
    number Virtually at: www.virtualshareholdermeeting.com/ILMN2025
    *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com
    THIS IS NOT A VOTABLE BALLOT
    This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.
    Board Voting Items Recommends
    1 . Election of Directors
    Nominees:
    1A Frances Arnold, Ph.D. For
    18 Caroline D. Dorsa For
    1( RobertS. Epstein, M.D. For
    1D Scott Gottlieb, M.D. For
    1 E Gary S. Guthart, Ph.D. For
    1F Keith A. Meister For
    1G Anna Richo For
    1H Philip W. Schiller For
    11 Susan E. Siegel For
    1J Jacob Thaysen, Ph.D. For
    1K Scott B. Ullem For
    2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal
    For year ending December 28, 2025.
    3. To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy
    For
    Statement.
    4. To approve the Second Amended and Restated 2015 Stock and Incentive Plan of lllumina, Inc. For
    NOTE: Such other business as may properly come before the meeting or any adjournment thereof. You may attend the Meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked with the arrow on your proxy card or Notice of Internet Availability of Proxy Materials available and follow the instructions.
    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

    Get the next $ILMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    11/12/2024$156.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Ullem Scott B. was granted 212 shares, increasing direct ownership by 3% to 8,601 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    1/5/26 4:47:12 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Legal Officer Davies Scott M sold $43,957 worth of shares (323 units at $136.09), decreasing direct ownership by 2% to 17,887 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    12/16/25 5:00:32 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ILMN
    SEC Filings

    View All

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AI, Genomics, and CRISPR Signal a New Phase of Biological Innovation

    DENVER, Feb. 10, 2026 (GLOBE NEWSWIRE) -- As artificial intelligence continues to move beyond software and automation, its impact on genomics and gene editing is becoming increasingly tangible. Recent developments among genomics and AI-enabled biotechnology companies suggest that AI-driven pattern recognition is emerging as a foundational layer for CRISPR-based innovation, with implications spanning human health and advanced biologically assembled materials. Illumina (NASDAQ:ILMN), the global leader in DNA sequencing, recently secured U.S. Medicare reimbursement for its TruSight™ Oncology Comprehensive test, expanding access to broad genomic profiling in routine cancer care. Increased rei

    2/10/26 9:29:10 AM ET
    $GH
    $ILMN
    $RXRX
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

    Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis)GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35Fiscal year 2025 results: Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basisEx-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basisGAAP operating margin of 18.6% and non-GAAP operating margin of 23.1%GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84Fiscal year 2026 guidance:

    2/5/26 4:06:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

    Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity with the latest multiomic technologies SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)'s Frozen Zoo®. The 50-year-old biobank is the world's most comprehensive and diverse collection of living cells from threatened and endangered species across the animal kingdom. Illumina will sequence up to 4,000 samples representing 1,300 species in the Frozen Zoo®. Genomic insights will be applied to rea

    2/3/26 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    2/5/26 4:09:49 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    1/30/26 9:06:44 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    1/13/26 9:11:40 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Scotiabank with a new price target

    Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

    7/11/25 8:11:04 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Citigroup reiterated coverage on Illumina with a new price target

    Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

    3/4/25 8:10:42 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Illumina Appoints Dr. Eric Green as Chief Medical Officer

    Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO  SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di

    1/8/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ILMN
    Financials

    Live finance-specific insights

    View All

    Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

    Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis)GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35Fiscal year 2025 results: Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basisEx-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basisGAAP operating margin of 18.6% and non-GAAP operating margin of 23.1%GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84Fiscal year 2026 guidance:

    2/5/26 4:06:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

    SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, February 5, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, February 5, 2026. Interested parties may access the live webcast via the Investor Info

    1/12/26 4:07:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

    Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basisGAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025Repurchased 1.2 million shares of our common stock for $120 million at an average price of $97.10 per shareFor fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (1.5%) to (0.5%), up from (2.5%) to (1.5%)Revenue growth outside of China in the range of 0.5% - 1.5% on a constant currency basis, with no ch

    10/30/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care